The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | AMG 420 BiTE for R/R multiple myeloma
The AMG 420 bi-specific T-cell engager (BiTE) therapy which targets the anti–B-cell maturation antigen (BCMA) is now being tested in relapsed/refractory multiple myeloma (MM). Here, Thierry Facon, MD, of Lille University Hospital, Lille, France, also discusses the latest data from the Phase I dose-escalation study (NCT02514239) assessing the safety, tolerability and anti‑tumor activity of AMG 420, a CD3 BiTE. Dr Facon presented the data at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA,
